**FADD deficiency mimicking ALPS-FAS: An expanding phenotype.**

Priyanka Setia1, Umair Ahmed Bargir1, Chandrakala S2, Neha Jodhawat1, Priyanka Kambli1, Maya Gupta1, Aparna Dalvi1, Shweta Shinde1, Nayana Nambiar1, Sneha Sawant1 ,Shraddha Shelar1 ,Pallavi Gaikwad1, Amruta Dhawale1, Madhu Mohanty3, Mukesh Agarwal4, Reetika Mallik Yadav1, Manisha Madkaikar1.

1: Indian Council of Medical Research (ICMR)- National Institute of Immunohaematology (NIIH), 13th-floor New multistorey building, KEM Hospital, Parel Mumbai.India

2: Department of Haematology, Seth G.S. Medical College and KEM hospital, Mumbai, India.

3: ICMR-NIV Mumbai unit (ERC), Haffkine institute compound, Parel, Mumbai, India

4: Department of Pediatrics, Seth G.S. Medical College and KEM hospital, Mumbai, India.

**E-mail: madkaikarmanisha@gmail.com**

**Table S4 :Blood profile and immunological features of heterozygous parents**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Father**  | **Mother**  | **Reference range** |
| **White Blood cells** | 7.4 **×** 109/L | 6.8× 109/L | 10±5 × 109/L |
| **Red Blood cells** | 5.65×1012/L | 4.7×1012/L | 4.6±0.6 ×1012/L |
| **Haemoglobin** | 15.6 gm/dL | 12.3 gm/dL | 12.5±1.5gm/dL |
| **Platelets** | 115× 109/L | 309 × 109/L | 200-490 **×** 109/L |
| **Neutrophils %** | 59%**-** 4.3 **×** 109/L-  | 55%- 3.7×109/L | 55-70% (1.5-8 × 109/L) |
| **Eosinophils %** | 3%-0.2 **×**109/L | 1%-0.06**×** 109/L | 1- 4% (0.1-1 × 109/L) |
| **Monocytes %** | 7%- 0.4 **×**109/L | 6%- 0.42×109/L | 2-8% (0.2-1.0) |
| **Lymphocytes%** | 31%**-** 2.2× 109/L | 38%-3× 109/L | 20-40% (6-9 × 109/L) |
| **Absolute lymphocyte count(ALC)** | 2294 count/mm3 | 2386 count/mm3 | 1400-3300 count/mm3 |
| **Basic Immunological evaluation** |
| **T cell % and absolute counts (count/mm3)\*** | 72% (1652) | 81% (1933) | 49-83% - (1000-2200) |
| **Th cell % and absolute counts (count/mm3)** | 40% (918) | 49% (1169) | 27-53% (530-1300) |
| **Tc cell % and absolute counts****(count/mm3)** | 29%(665) | 27% (644) | 16-40% (330-920) |
| **B cell % and absolute counts (count/mm3)** | 9% (206) | 13% (310) | 2-27% - (110-570) |
| **NK cell % and absolute counts (count/mm3)** | 15% (344) | 5% (119) | 2-27% - (70-480) |
| **Immunoglobulin levels** |
| **IgG** | - | - | 4-15.9 g/L |
| **IgA** | - | - | 0.17-2.90 g/L |
| **IgM** | - | - | 0.34-3.48 g/L |
| **IgE** | **-** | - | 3-423 IU/ml |
| **CD4 -T helper cell (Th) cell evaluation** |
| **Th naïve (CD3+CD4+CD45RA+CD27+)** | 25 | 48 | 16-100% |
| **Th central memory (CD3+CD4+CD45RA-CD27+)** | 63 | 44 | 18-95% |
| **Th effector memory (CD3+CD4+CD45RA-CD27-)** | 12 | 8 | 1-23% |
| **Th TEMRA (CD3+CD4+CD45RA+CD27-)** | 0.1 | 0.25 | 0.0083-6.8% |
| **T regulatory cells (Tregs)****CD3+CD4+ CD127 low CD25 high** | 7.5% | 6.45% | 3-14% |
| **CD8- Cytotoxic T (Tc) cell evaluation** |
| **Tc naïve (CD3+CD8+CD45RA+CD27+)** | 15 | 40 | 06-100% |
| **Tc central memory (CD3+CD8+CD45RA-CD27+)** | 27 | 23 | 1-20% |
| **Tc effector memory (CD3+CD8+CD45RA-CD27-)** | 16 | 13 | 14-98% |
| **Tc TEMRA (CD3+CD8+CD45RA+CD27-)** | 41 | 23 | 7-53% |
| **B cell evaluation** |
| **B memory** **(CD19+CD27+)** | **32** | **41** | 7-29% |
| **Class switch memory (CD19+CD27+IgM- IgD-)** | **16** | **27** | 0.8-9.1% |
| **CD21 low B cell** **(CD19+CD38-CD21low)** | 2.7 | 1.7 | 0.9-7% |
| **Plasma blasts** **(CD19+ CD27+CD38 high)** | 0.39 | **0.29** |  0.4-3.6% |
| **Transitional B cells** | 0.69 | **0.07** | 0.6-3.4% |
| **DNT evaluation** |
| **DNTs** | 0.5% | 1.9% | <2.5% of total T cells |
| **B220 expression on DNTs** | 8% | 4% | <60%  |
| **HLADR+ CD45RA+ DNTs** | 9.6% | 5.7% | <20% |
| **Fas controlled (FC) DNTs** | 23% | 25% | <30% |
| **Biomarker evaluation** |
| **IL-10 levels** | 2 pg/ml | - | <20 pg/ml |
| **Vitamin B12 levels**  | **-** | - | <1500 pg/L |
| **IL-18 levels** | 13.2 pg/ml | - | <500 pg/ml |
| **sFASL levels** | 15.8 pg/ml | - | <200 pg/ml |
| **sIL-2Rα** | 2098 | - | 1353-45907 units/ml |